Disc Medicine Quarterly Balance Sheets Chart
Quarterly
|
Annual
Disc Medicine Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||
| current assets: | ||||||||||||||||||
| cash and cash equivalents | 127,337,000 | 122,675,000 | 192,434,000 | 192,638,000 | 280,663,000 | 342,615,000 | 360,382,000 | 370,541,000 | 377,602,000 | 236,422,000 | 194,611,000 | 101,737,000 | 108,659,000 | 119,064,000 | 136,627,000 | 150,069,000 | 167,477,000 | 184,986,000 |
| marketable securities | 522,636,000 | 571,987,000 | 297,447,000 | 294,725,000 | 220,282,000 | |||||||||||||
| prepaid expenses and other current assets | 11,619,000 | 10,938,000 | 3,734,000 | 5,789,000 | 7,296,000 | 9,333,000 | 5,280,000 | 3,722,000 | 4,131,000 | 5,716,000 | 3,880,000 | 2,927,000 | 4,470,000 | 4,681,000 | 3,250,000 | 4,731,000 | 3,834,000 | 3,619,000 |
| total current assets | 661,592,000 | 705,600,000 | 493,615,000 | 493,152,000 | 508,241,000 | 351,948,000 | 365,662,000 | 374,263,000 | 381,733,000 | 242,138,000 | 198,491,000 | 104,664,000 | 113,129,000 | 124,068,000 | 140,100,000 | 154,800,000 | 171,311,000 | 188,605,000 |
| property and equipment | 1,289,000 | 1,370,000 | 751,000 | 79,000 | 98,000 | 211,000 | 170,000 | 183,000 | 159,000 | 180,000 | 168,000 | 180,000 | 229,000 | 229,000 | ||||
| right-of-use assets, operating leases | 1,340,000 | 1,457,000 | 1,569,000 | 1,678,000 | 1,642,000 | 1,788,000 | 1,930,000 | 1,935,000 | 2,166,000 | 1,346,000 | 1,430,000 | |||||||
| other assets | 840,000 | 839,000 | 838,000 | 236,000 | 236,000 | 235,000 | 234,000 | 116,000 | 116,000 | 116,000 | 116,000 | 1,367,000 | 204,000 | 217,000 | 237,000 | 232,000 | 559,000 | 225,000 |
| total assets | 665,061,000 | 709,266,000 | 496,773,000 | 495,145,000 | 510,217,000 | 354,182,000 | 367,996,000 | 376,497,000 | 384,174,000 | 243,780,000 | 200,205,000 | 106,031,000 | 113,333,000 | 124,285,000 | 140,437,000 | 155,535,000 | 172,422,000 | 189,382,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||
| current liabilities: | ||||||||||||||||||
| accounts payable | 6,350,000 | 6,703,000 | 7,948,000 | 3,553,000 | 4,749,000 | 5,269,000 | 12,629,000 | 8,496,000 | 5,214,000 | 5,642,000 | 16,162,000 | 1,139,000 | 1,618,000 | 5,110,000 | 2,950,000 | 939,000 | 1,492,000 | 3,562,000 |
| accrued external research and development expenses | 7,463,000 | 7,421,000 | 7,141,000 | 16,332,000 | 10,351,000 | |||||||||||||
| other accrued expenses | 6,161,000 | 4,138,000 | 8,097,000 | 5,512,000 | 4,451,000 | |||||||||||||
| operating lease liabilities, current | 632,000 | 479,000 | 130,000 | 76,000 | 759,000 | 767,000 | 665,000 | 353,000 | 321,000 | 313,000 | 307,000 | |||||||
| total current liabilities | 20,606,000 | 18,741,000 | 23,316,000 | 25,473,000 | 20,310,000 | 14,852,000 | 21,439,000 | 14,416,000 | 9,683,000 | 9,980,000 | 22,578,000 | 1,464,000 | 6,436,000 | 12,674,000 | 14,834,000 | 12,661,000 | 11,505,000 | 13,776,000 |
| long-term debt | 28,737,000 | 28,529,000 | 28,322,000 | |||||||||||||||
| operating lease liabilities, non-current | 1,553,000 | 1,634,000 | 1,548,000 | 1,712,000 | 1,078,000 | 1,259,000 | 1,436,000 | 1,607,000 | 1,772,000 | 945,000 | 1,027,000 | |||||||
| total liabilities | 50,896,000 | 48,904,000 | 53,186,000 | 27,185,000 | 21,388,000 | 16,111,000 | 22,875,000 | 17,523,000 | 12,955,000 | 10,925,000 | 23,605,000 | 1,464,000 | 6,436,000 | 12,674,000 | 15,596,000 | 14,674,000 | 14,740,000 | 18,221,000 |
| commitments and contingencies | ||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized, no shares issued or outstanding as of june 30, 2025 and december 31, 2024 | ||||||||||||||||||
| common stock | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 |
| additional paid-in capital | 1,001,223,000 | 991,911,000 | 741,297,000 | 735,761,000 | 730,832,000 | 553,663,000 | 533,764,000 | 524,038,000 | 522,161,000 | 367,850,000 | 288,814,000 | 314,851,000 | 313,904,000 | 311,528,000 | 309,527,000 | 307,724,000 | 305,994,000 | 303,026,000 |
| accumulated other comprehensive income | 273,000 | 535,000 | 289,000 | 741,000 | ||||||||||||||
| accumulated deficit | -387,334,000 | -332,087,000 | -298,002,000 | -268,545,000 | -241,946,000 | -215,594,000 | -188,645,000 | -165,066,000 | -150,944,000 | -134,997,000 | -112,216,000 | -210,288,000 | -207,011,000 | -199,921,000 | -184,690,000 | -166,867,000 | -148,316,000 | -131,869,000 |
| total stockholders’ equity | 614,165,000 | 660,362,000 | 443,587,000 | 467,960,000 | 488,829,000 | 338,071,000 | 345,121,000 | 358,974,000 | 371,219,000 | 232,855,000 | 176,600,000 | 124,841,000 | ||||||
| total liabilities and stockholders’ equity | 665,061,000 | 709,266,000 | 496,773,000 | 495,145,000 | 510,217,000 | 354,182,000 | 367,996,000 | 376,497,000 | 384,174,000 | 243,780,000 | 140,437,000 | |||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized, no shares issued or outstanding as of march 31, 2025 and december 31, 2024 | ||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized, no shares issued or outstanding as of december 31, 2024 and december 31, 2023 | ||||||||||||||||||
| accumulated other comprehensive loss | -60,000 | |||||||||||||||||
| accrued expenses | 8,816,000 | 8,145,000 | 5,567,000 | 4,148,000 | 4,025,000 | 6,109,000 | ||||||||||||
| contingent value right liability | 1,500,000 | 1,500,000 | ||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ equity | ||||||||||||||||||
| derivative liability | ||||||||||||||||||
| series seed convertible preferred stock, 0.0001 par value; no shares and 5,000,000 shares authorized at december 31, 2022 and 2021, respectively; no shares and 5,000,000 shares issued and outstanding as of december 31, 2022 and 2021, respectively; | ||||||||||||||||||
| series a convertible preferred stock, 0.0001 par value; no shares and 41,666,666 shares authorized as of december 31, 2022 and 2021, respectively; no shares and 41,666,666 shares issued and outstanding as of december 31, 2022 and 2021, respectively; | ||||||||||||||||||
| series b convertible preferred stock, 0.0001 par value; no shares and 37,499,999 shares authorized as of december 31, 2022 and 2021, respectively; no shares and 37,499,999 shares issued and outstanding as of december 31, 2022 and 2021, respectively; | ||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 200,205,000 | |||||||||||||||||
| restricted cash, current | 323,000 | 223,000 | ||||||||||||||||
| restricted cash, non-current | 100,000 | |||||||||||||||||
| liabilities and stockholders' equity | ||||||||||||||||||
| accrued expenses and other current liabilities | 325,000 | 1,905,000 | 3,405,000 | 6,884,000 | 6,722,000 | 5,013,000 | 5,214,000 | |||||||||||
| term loan, current portion | 2,913,000 | 4,159,000 | 5,000,000 | 5,000,000 | 5,000,000 | 5,000,000 | ||||||||||||
| other liabilities | 358,000 | 366,000 | 346,000 | 316,000 | ||||||||||||||
| term loan, net of current portion and discount | 404,000 | 1,647,000 | 2,889,000 | 4,129,000 | ||||||||||||||
| stockholders' equity: | ||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of september 30, 2022 and december 31, 2021 | ||||||||||||||||||
| total stockholders' equity | 104,567,000 | 106,897,000 | 111,611,000 | 140,861,000 | 157,682,000 | 171,161,000 | ||||||||||||
| total liabilities and stockholders' equity | 106,031,000 | 113,333,000 | 124,285,000 | 155,535,000 | 172,422,000 | 189,382,000 | ||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of june 30, 2022 and december 31, 2021 | ||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of march 31, 2022 and december 31, 2021 | ||||||||||||||||||
| deferred offering costs | ||||||||||||||||||
| convertible notes | ||||||||||||||||||
| warrant liability | ||||||||||||||||||
| stockholders' equity | ||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of december 31, 2021 and 2020 | ||||||||||||||||||
| restricted cash | 323,000 | 323,000 | 323,000 | |||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of september 30, 2021 and december 31, 2020 | ||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of june 30, 2021 and december 31, 2020 | ||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of march 31, 2021 and december 31, 2020 |
We provide you with 20 years of balance sheets for Disc Medicine stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Disc Medicine. Explore the full financial landscape of Disc Medicine stock with our expertly curated balance sheets.
The information provided in this report about Disc Medicine stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.